Skip to content
HowShorted

Atara Biotherapeutics, Inc. short interest in 2018

In 2018, Atara Biotherapeutics, Inc.'s disclosed short interest ran from 16.97% of shares outstanding on 12 Jan 2018 to 14.37% on 31 Dec 2018, a change of -2.60 percentage points. The year's high was 21.80% on 13 Apr 2018 and its low 13.16% on 15 Oct 2018, averaging 15.33% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 18.01 days on 31 Jul 2018. Full history: Atara Biotherapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Atara Biotherapeutics, Inc. in 2018

2018 in figures

Start of year
16.97% (12 Jan 2018)
End of year
14.37% (31 Dec 2018)
Change
-2.60 pp
High
21.80% (13 Apr 2018)
Low
13.16% (15 Oct 2018)
Average
15.33%
Highest days to cover
18.01 (31 Jul 2018)
SEC filings marked
8

Every report in 2018

Atara Biotherapeutics, Inc. short interest in 2018
SettlementShort interestDays to coverFilings since previous
12 Jan 201816.97%3.64
31 Jan 201815.74%3.52
15 Feb 201816.40%4.81
28 Feb 201816.30%7.3710-K filed, results (8-K)
15 Mar 201814.15%4.57
29 Mar 201817.73%5.85
13 Apr 201821.80%10.92
30 Apr 201815.40%14.39
15 May 201815.00%14.6210-Q filed, results (8-K)
31 May 201815.97%12.20
15 Jun 201815.25%10.57
29 Jun 201816.22%8.19
13 Jul 201815.25%16.28
31 Jul 201814.98%18.01
15 Aug 201814.10%12.6110-Q filed, results (8-K)
31 Aug 201813.64%12.01
14 Sep 201813.71%11.00
28 Sep 201814.15%6.86
15 Oct 201813.16%11.84
31 Oct 201814.38%15.28
15 Nov 201814.10%10.6010-Q filed, results (8-K)
30 Nov 201814.34%11.10
14 Dec 201814.83%12.86
31 Dec 201814.37%13.09

See also: Atara Biotherapeutics, Inc.'s full history · most shorted US stocks of 2018 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.